Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra‐Rapid Lispro: A Comparative Clamp Study in Healthy Volunteers
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1497 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Sergei Noskov und 8 weiteren Autor:innen. Beteiligte Einrichtung: City Hospital No. 3, Yaroslavl, Russia. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Insulin Lispro, Hypoglycemic Agents. Die Arbeit nennt 21 Literaturangaben.
Abstract (Originalsprache)
Ultra‐rapid insulin lispro is an innovative insulin analogue designed to achieve rapid onset and short duration of action, aimed at optimizing glycemic control in patients with diabetes. This was a double‐blind, randomized, 2‐period, crossover clamp study to evaluate the pharmacokinetics (PK) and pharmacodynamics (PD), along with safety profiles, of a potential biosimilar ultra‐rapid insulin lispro compared to the reference product in healthy White men. A total of 35 healthy volunteers completed hyperinsulinemic euglycemic clamp procedures across both study periods. Blood samples were collected at predefined intervals up to 8 hours to assess PK parameters. Plasma glucose levels were monitored every 5 minutes during the 8‐hour clamps, with adjustments to the glucose infusion rate to maintain the target range. Insulin quantification in plasma was conducted using a validated enzyme‐linked immunosorbent assay method. PD assessment was based on glucose infusion rate profiles during both clamps. Geometric mean ratios for maximum plasma concentration and area under the concentration‐time curve from insulin administration to the last measurable concentration for the test and reference drugs fell within the bioequivalence range of 80%‐125%. Furthermore, the investigational drugs demonstrated comparable PK/PD profiles of insulin lispro. Both formulations exhibited similar safety profiles primarily characterized by mild injection site reactions.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- City Hospital No. 3, Yaroslavl, Russia.
- Endocrinology Research Center, Moscow, Russia.
- R&D Center, GEROPHARM, Saint-Petersburg, Russia.
Zitieren
APA
Noskov, S., Koksharova, E., Arefeva, A., Banko, V., Radaeva, K., Matvienko, I., Gefen, M., Makarenko, I., & Drai, R. (2025). Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra‐Rapid Lispro: A Comparative Clamp Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1497
Vancouver
Noskov S, Koksharova E, Arefeva A, Banko V, Radaeva K, Matvienko I, et al. Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra‐Rapid Lispro: A Comparative Clamp Study in Healthy Volunteers. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1497
BibTeX
@article{Noskov2025,
author = {Noskov, Sergei and Koksharova, Ekaterina and Arefeva, Anna and Banko, Veniamin and Radaeva, Kseniia and Matvienko, Iuliia and Gefen, Maria and Makarenko, Igor and Drai, Roman},
title = {Pharmacokinetic and Pharmacodynamic Equivalence of Biosimilar and Reference Ultra‐Rapid Lispro: A Comparative Clamp Study in Healthy Volunteers},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1497}
}
EUVIMED